Formulation Development
ArTara Therapeutics Completes Merger Transaction With Proteon Therapeutics
ArTara Therapeutics, Inc. recently announced the completion of the merger with Proteon Therapeutics, Inc.and associated equity financing. The merged company will operate under the name…
Cytovia Therapeutics & the University of California, San Francisco Enter Partnership to Develop Precision Gene-Edited CAR-NK Cell Therapy
Cytovia Therapeutics and the University of California, San Francisco (UCSF) recently announced they have entered a 3-year research partnership to develop novel precision gene editing…
Acceleron & Fulcrum Therapeutics Announce Pulmonary Research & Discovery Collaboration Agreement
Acceleron Pharma Inc. and Fulcrum Therapeutics, Inc. recently announced they have entered into a collaboration and license agreement to identify small molecules designed to modulate…
WuXi STA Opens Oligonucleotide Large-Scale Manufacturing Facility
STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – recently announced the opening of its large-scale oligonucleotide active pharmaceutical ingredient (API)…
Pfenex Earns $15-Million Development Milestone Under its Development & License Agreement
Pfenex Inc. recently announced it has earned a $15-million development milestone under its development and license agreement with Jazz Pharmaceuticals plc. The milestone is associated…
Opiant Pharmaceuticals Announces Development Collaboration With National Center for Advancing Translational Sciences
Opiant Pharmaceuticals, Inc. recently announced it has signed a Letter of Intent with the National Center for Advancing Translational Sciences (NCATS) to collaborate on the…
FDA Approves Intra-Cellular Therapies’ Novel Treatment of Schizophrenia in Adults
Intra-Cellular Therapies, Inc. recently announced that CAPLYTA (lumateperone) has been approved by the US FDA for the treatment of schizophrenia in adults. The company expects…
Bioiberica Launches Natural Origin Thyroid
Bioiberica, a world reference in the identification, extraction, and development of animal-derived APIs, recently announced the launch of its natural thyroid active pharmaceutical ingredient (API) for the treatment of…..
Tetra Bio-Pharma Provides Update on its Hepatocellular Carcinoma Drug
Tetra Bio-Pharma Inc. recently announced it will be requesting a meeting with the US FDA to discuss the drug development program for its Orphan Drug candidate HCC011….
Catalent Partners With Bridge Therapeutics on Formulation, Development & Production of New Opioid Addiction Treatment
Catalent recently announced it has completed clinical production of Bridge Therapeutics Inc.’s (Bridge) opioid addiction development therapeutic product, BT-219, and executed an….
Tonix Pharmaceuticals Enrolls First Patient in Phase 3 RELIEF Study
Tonix Pharmaceuticals Holding Corp. recently announced that the first patient was enrolled in the Phase 3 RELIEF study (TNX-CY-F304)……
Inceptua Medicines Access & Onconova Therapeutics Announce Pre-Approval Access Collaboration
Onconova Therapeutics, Inc. and Inceptua Medicines Access (a business unit of the Inceptua Group) recently announced they have entered into a collaboration to make available…
Fate Therapeutics Presents its First Off-the-Shelf, iPSC-Derived CAR T-Cell Immunotherapy Program
Fate Therapeutics, Inc. recently announced new in vivo preclinical data for FT819, its first off-the-shelf, iPSC-derived chimeric antigen receptor (CAR) T-cell product candidate, at the…
Retrogenix & Resonant Therapeutics Announce Strategic Alliance
Retrogenix and Resonant Therapeutics, Inc. recently announced they have entered into a non-exclusive strategic partnership to identify the targets of Resonant antibodies directed against the…
Navigen Announces FDA Clearance of its IND Application
Navigen, Inc. recently announced the US FDA has cleared its Investigational New Drug application (IND) for the initiation of a Phase 1 study in healthy…
Bioncotech Therapeutics Announces Oncology Clinical Trial Collaboration With MSD
Bioncotech Therapeutics recently announced it has entered into a Phase 2 clinical trial collaboration with a subsidiary of Merck & Co., Inc., Kenilworth, NJ, known…
Appili Therapeutics Enters Commercial Agreement With Saptalis Pharmaceuticals
Appili Therapeutics Inc. recently announced it has entered into a commercialization agreement with Saptalis Pharmaceuticals LLC on ATI-1501, Appili’s liquid suspension reformulation of the…..
Biogen Announces Positive Phase 2 Study Results
Biogen Inc. recently announced positive top-line results from the Phase 2 LILAC study evaluating the efficacy and safety of BIIB059, a fully humanized….
OWP Pharmaceuticals Announces Second IND Approval & Patent Application for First-Ever Liquid Oral Suspension Formulation
OWP Pharmaceuticals, Inc. recently announced today that it has received Investigational New Drug (IND) approval from the US FDA, and has submitted for US patent protection, for the first-ever liquid formulation of….
Dermavant Announces First Patient Dosed in Phase 2a Clinical Trial
Dermavant Sciences recently announced that the first patient has been dosed in its Phase 2a vitiligo clinical trial for topical cerdulatinib. Cerdulatinib is a dual…
